A further series of executive changes at Alexion Pharmaceuticals Inc. has been cautiously welcomed as an opportunity for recently appointed new CEO Ludwig Hantson to build his own team and have a complete break from past company missteps, but observers are questioning whether the changes are sufficient to boost confidence in the US company.
The ultra-rare disease drug developer was rocked by a sales audit investigation at the end of last year - that...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?